William Troutman in a hospital chair receives IV treatment. He holds up seven fingers to mark his seventh day of treatment.


Download

Last fall, Tzield was approved to delay type 1 diabetes in people predicted to develop it. This week, I’m talking one of the first families to use what used to be called Teplizumab for their son, as a regular patient, outside the clinical trials. How exactly does this all work? Who’s eligible and how do you cover the enormous financial cost?

Amanda Troutman talks about why they went through this process with her son, William. Their whole family was tested for the genetic markers after their daughter, Jenna, was diagnosed in 2020.

As always, this podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Our previous episodes on Tzield: https://diabetes-connections.com/?s=teplizumab

More about the Troutman family: https://www.vcuhealth.org/news/north-carolina-teen-among-first-in-us-to-receive-new-diabetes-drug

Please visit our Sponsors & Partners – they help make the show possible!

Take Control with Afrezza 

Omnipod – Simplify Life

Learn about Dexcom 

Check out VIVI Cap to protect your insulin from extreme temperatures

Learn more about AG1 from Athletic Greens 

Drive research that matters through the T1D Exchange

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

Sign up for our newsletter here

Here’s where to find us:

Facebook (Group)

Facebook (Page)

Instagram

Twitter

Check out Stacey’s books!

Learn more about everything at our home page www.diabetes-connections.com 

Reach out with questions or comments: info@diabetes-connections.com

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Post comment